Based on limited published evidence, EID2B functions as a transcriptional repressor that negatively regulates MYOD-dependent transcription, glucocorticoid receptor signaling, and myoblast differentiation. UniProt and GO annotations indicate EID2B acts as a transcription corepressor localized to the nucleus/nucleoplasm through protein-binding interactions. Recent research demonstrates that exosomal miR-92a-3p targets EID2B in colorectal cancer, where EID2B downregulation promotes M2 macrophage polarization via MAPK/ERK pathway activation, facilitating tumor migration and angiogenesis 1.